CP-105,696
|
|
|
- CAS-Nr.
- 158081-99-3
- Englisch Name:
- CP-105,696
- Synonyma:
- CP-105,696;Pfizer 105696;UNII-Z7354TW4BM;CP105696,CP 105696;CP-105,696 >=98% (HPLC);CP105696 (Pfizer 105696);CP 105696; CP105696; CP-105696; UNII-Z7354TW4BM; PFIZER 105696;1-((3S,4R)-3-([1,1'-biphenyl]-4-ylmethyl)-4-hydroxychroman-7-yl)cyclopentanecarboxylic acid;1-((3S,4R)-3-([1,1'-Biphenyl]-4-ylmethyl)-4-hydroxychroman-7-yl)cyclopentanecarboxylic acid;1-((3S,4R)-3-([1,1'-biphenyl]-4-ylmethyl)-4-hydroxychroman-7-yl)cyclopentane-1-carboxylic acid
- CBNumber:
- CB84741785
- Summenformel:
- C28H28O4
- Molgewicht:
- 428.52
- MOL-Datei:
- 158081-99-3.mol
|
CP-105,696 Eigenschaften
- Siedepunkt:
- 651.2±55.0 °C(Predicted)
- Dichte
- 1.252±0.06 g/cm3(Predicted)
- storage temp.
- room temp
- L?slichkeit
- Soluble in DMSO
- pka
- 4.35±0.20(Predicted)
- Aggregatzustand
- powder
- Farbe
- white to beige
Sicherheit
- Risiko- und Sicherheitserkl?rung
- Gefahreninformationscode (GHS)
| Bildanzeige (GHS) |
|
| Alarmwort |
Warnung |
| Gefahrenhinweise |
| Code |
Gefahrenhinweise |
Gefahrenklasse |
Abteilung |
Alarmwort |
Symbol |
P-Code |
| H302 |
Gesundheitssch?dlich bei Verschlucken. |
Akute Toxizit?t oral |
Kategorie 4 |
Warnung |
![GHS hazard pictograms]() src="/GHS07.jpg" width="20" height="20" /> |
P264, P270, P301+P312, P330, P501 |
|
| Sicherheit |
| P264 |
Nach Gebrauch gründlich waschen. |
| P264 |
Nach Gebrauch gründlich waschen. |
| P270 |
Bei Gebrauch nicht essen, trinken oder rauchen. |
| P501 |
Inhalt/Beh?lter ... (Entsorgungsvorschriften vom Hersteller anzugeben) zuführen. |
|
CP-105,696 Chemische Eigenschaften,Einsatz,Produktion Methoden
Verwenden
CP-105,696 has been used as a leukotriene B4 receptor (LTB4R) antagonist to study the influence of the LTB4 pathway in the pathogenesis of acute itch flares in irritant calcipotriol (MC903)+ model allergen ovalbumin (OVA) sensitized murine model of atopic dermatitis (AD)-like disease.
Biochem/physiol Actions
CP-105,696 is an orally active, potent and selective leukotriene B4 receptor (LTB4R) antagonist (IC50 against [3H]LTB4 = 5.6 nM for binding human neutrophils; IC50 = 9.7 nM & 30.3 nM, respectively using guinea pig spleen or mouse membranes) that targets LTB4R high- and low-affinity binding sites in a LTB4 non-competitive and competitive manner, respectively. CP-105,696 inhibits 5 nM LTB4-induced human neutrophils chemotaxis and CDllb upregualtion (IC50 = 5.2 nM and 430 nM, respectively) without inhibiting cyclooxygenase activity or affecting chemotaxis induced by C5a, PAF, IL-8. Oral administration is efficacious against intradermal LTB4 (100 ng/mouse), but not IL-1, injection-induced neutrophil accumulation in mice and guinea pigs (ED50 = 4.2 and 0.26 mgkg, respectively). CP-105,696 in vivo efficacy is also demonstrated in other animal models, including collagen-induced arthritis (CIA; 0.3-10 mg/kg in mice), allergic encephalomyelitis (ED50= 8.6 mg/kg; mice), and asthma (10-30 mg/kg; primate).
CP-105,696 Upstream-Materialien And Downstream Produkte
Upstream-Materialien
Downstream Produkte
CP-105,696 Anbieter Lieferant Produzent Hersteller Vertrieb H?ndler.
Global( 33)Lieferanten
- CP-105,696
- 1-[(3S,4R)-4-hydroxy-3-[(4-phenylphenyl)methyl]-3,4-dihydro-2H-chromen-7-yl]cyclopentane-1-carboxylic acid
- 1-((3S,4R)-3-([1,1'-biphenyl]-4-ylmethyl)-4-hydroxychroman-7-yl)cyclopentane-1-carboxylic acid
- CP 105696; CP105696; CP-105696; UNII-Z7354TW4BM; PFIZER 105696
- Pfizer 105696
- UNII-Z7354TW4BM
- Cyclopentanecarboxylic acid, 1-[(3S,4R)-3-([1,1'-biphenyl]-4-ylmethyl)-3,4-dihydro-4-hydroxy-2H-1-benzopyran-7-yl]-
- CP-105,696 >=98% (HPLC)
- CP105696 (Pfizer 105696)
- CP105696,CP 105696
- 1-((3S,4R)-3-([1,1'-biphenyl]-4-ylmethyl)-4-hydroxychroman-7-yl)cyclopentanecarboxylic acid
- 1-((3S,4R)-3-([1,1'-Biphenyl]-4-ylmethyl)-4-hydroxychroman-7-yl)cyclopentanecarboxylic acid
- 1-((3S,4R)-3-([1,1'-Biphenyl]-4-ylmethyl)-4-hydroxychroman-7-yl)cyclopentane-1-carboxylic acid
- 1-[(3S,4R)-3-({[1,1'-biphenyl]-4-yl}methyl)-4-hydroxy-3,4-dihydro-2H-1-benzopyran-7-yl]cyclopentane-1-carboxylic acid
- 158081-99-3
- API
